Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $32.1 million.

  • Editas Medicine's Operating Expenses fell 5117.53% to $32.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.2 million, marking a year-over-year decrease of 1551.92%. This contributed to the annual value of $283.5 million for FY2024, which is 1462.25% up from last year.
  • As of Q3 2025, Editas Medicine's Operating Expenses stood at $32.1 million, which was down 5117.53% from $55.1 million recorded in Q2 2025.
  • Editas Medicine's Operating Expenses' 5-year high stood at $84.0 million during Q4 2023, with a 5-year trough of $32.1 million in Q3 2025.
  • Over the past 5 years, Editas Medicine's median Operating Expenses value was $60.6 million (recorded in 2022), while the average stood at $61.2 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 5413.89% in 2024, then plummeted by 5117.53% in 2025.
  • Quarter analysis of 5 years shows Editas Medicine's Operating Expenses stood at $54.1 million in 2021, then increased by 29.41% to $70.0 million in 2022, then increased by 20.05% to $84.0 million in 2023, then dropped by 8.11% to $77.2 million in 2024, then tumbled by 58.43% to $32.1 million in 2025.
  • Its last three reported values are $32.1 million in Q3 2025, $55.1 million for Q2 2025, and $80.8 million during Q1 2025.